{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-25-008617","form_type":"8-K","ticker":"AIM","cik":"0000946644","company_name":"AIM ImmunoTech Inc.","filed_at":"2025-02-28T23:59:59+00:00","discovered_at":"2026-05-14T18:03:06.908746+00:00","generated_at":"2026-05-26T00:52:01.827466+00:00","sec_items":["8.01","9.01"],"event_type":"regulatory","sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"confidence":"high","headline":"NYSE American accepts AIM ImmunoTech's plan to regain listing compliance; deadline June 11, 2026","bullets":["Plan accepted under Sections 1003(a)(ii) and 1003(a)(iii) of NYSE American Company Guide.","AIM has until June 11, 2026 to meet minimum stockholders' equity requirements.","CEO Thomas K. Equels expressed confidence in executing the strategy.","Company continues oncology and antiviral pipeline development alongside compliance efforts."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-25-008617","json":"https://secwatch.observer/filing/0001493152-25-008617.json","markdown":"https://secwatch.observer/filing/0001493152-25-008617.md","text":"https://secwatch.observer/filing/0001493152-25-008617.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/946644/000149315225008617/0001493152-25-008617-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/946644/000149315225008617/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-26T00:52:01.827466+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}